Healthy Elder PeopleNCT07801521
Feru-guard and General Antioxidant Capacity in Older People
A study testing Feru-guard in people with Healthy Elder People, run by Oregon Health and Science University at 1 site in United States.
Trial summary
To determine if Feru-guard, a dietary supplement, can decrease general oxidation and inflammation in people who are ages 65-89 years old. Also to determine if Feru-guard is safe in older people when given for 3 months. Read more about this study
- Who is it for?
- Ages 65 to 89 years
- Conditions the study is for
- Healthy Elder People
- What is being tested?
- Feru-guard
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 70 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Nov 2026to 31 Jul 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 to 89 years
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- 65 to 89 years old
- Not demented or mild cognitive impairment, defined as Clinical Dementia Rating (CDR) =0 and MMSE >24.
- Informant has direct contact with participant at least 2 days per week to verify functional status, CDR, and accompany participant to in-clinic screening visit
- Sufficient English language skills to complete all testing.
Who cannot join
- Any dementing illness (AD, vascular dementia, normal pressure hydrocephalus, or Parkinson's disease); dementia defined by CDR ≥ 0.50, MMSE < 25
- AD medication (e.g. acetylcholinesterase inhibitors, NMDA receptor agonist, disease-modifying monoclonal antibody immunotherapy (e.g. lecanemab))
- Significant disease of the CNS such as brain tumor, seizure disorder, subdural hematoma, cranial arteritis
- Alcohol or substance abuse according to DSM-IV criteria within the last 2 years
- Major depression, schizophrenia, or other major psychiatric disorder defined by DSM-IV criteria
- Participants on blood thinners such as warfarin (Coumadin, jantoven), rivaroxaban (xarelto), fondaparinux (arixtra), dibigatran (pradaxa), apixaban (eliquis) dalteparin (fragmin), enoxaparin (lovenox). Aspirin use is allowed.
Show all 17Show fewer
- Participants with malignancy or an acute inflammatory disease.
- Participants with critical cardiovascular, circulatory, respiratory, kidney, or liver disease or diabetes
- Illness that requires >1 visit /month to a clinician
- BMI of >30
- Cancer within the last 5 years, with the exception of localized prostate cancer (Gleason Grade < 3) and non-metastatic skin cancers (melanoma).
- Medications:
- CNS active meds that have not been on stable doses for at least 2 months (cimetidine, beta-blockers, and SSRIs)
- Neuroleptics, antiparkinsonian agents, systemic corticosteroids, and narcotic analgesics; in the case where these were used for a self-limited time they must have been discounted for a period of five half-lives prior to baseline visit
- Over the counter supplements are not by themselves exclusionary, however, subjects are asked not to change the dosing regimen over the course of the trial unless medically indicated; the presence and dose of these agents are recorded
- Participants who have taken Feru-guard, ferulic acid, or Angelica archangelica supplementation within the last year.
- Enrollment in another clinical trial or treatment study within the previous 6 months.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Oregon Health & Science University
Portland, Oregon, 97239
Lynne Shinto, ND, MPH, (503) 494-5035, shintol@ohsu.edu
About this study
Official title: Feru-guard (Ferulic Acid and Angelica Archangelica Extract) and General Antioxidant Capacity in Older People
To determine if Feru-guard, a dietary supplement, can decrease general oxidation and inflammation in people who are ages 65-89 years old. Also to determine if Feru-guard is safe in older people when given for 3 months.
- Conditions
- Healthy Elder People
- Being tested
- Feru-guard, Placebo
- Keywords
- ferulic acid, antioxidant, antiinflammatory, healthy elder people
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Feru-guardDietary supplement
Ferulic acid and Angelica dietary supplement in capsules
PlaceboOther
Placebo capsules
| Study group | Role | What they receive |
|---|---|---|
| Feru-guard | Experimental | Feru-guard capsules Receives: Dietary Supplement: Feru-guard |
| Placebo Group | Placebo comparator | Placebo capsules that are matched in size, and color Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Anti-oxidant Measure
general oxidative stress marker malondialdehyde (MDA),
Measured: 12 Weeks
general oxidative stress marker malondialdehyde (MDA),
Measured: 12 weeks
Anti-inflammatory measure
an inflammatory marker tumor necrosis factor alpha (TNF-alpha).
Measured: 12 weeks
Secondary outcomes (1)
Adverse Events
Adverse Event Report
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Sep 2026
- Study start15 Nov 2026 (estimated)
- Primary completion30 Apr 2028 (estimated)
- Study completion31 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy Elder PeopleStudies of the same condition, open and under way.
- More trials run by Oregon Health and Science UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized, Double-Blind, Placebo-Controlled Study
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Oregon Health and Science University
- Sponsor type
- University, hospital or other
- Collaborators
- Glovia Co., Ltd.
- Responsible party
- Principal investigator, Lynne Shinto, ND, MPH, Oregon Health and Science University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07801521
- Sponsor's protocol ID
- 17966
- Status last verified
- Aug 2026
- First submitted
- 31 Aug 2026
- Last updated
- 3 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feru-guard (Ferulic Acid and Angelica Archangelica Extract) and General Antioxidant Capacity in Older People
- ClinicalTrials.gov ID
- NCT07801521
- Acronym / sponsor ID
- 17966
- Conditions
- Healthy Elder People
- Keywords
- ferulic acid, antioxidant, antiinflammatory, healthy elder people
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Oregon Health and Science UniversityUniversity, hospital or other
- Collaborators
- Glovia Co., Ltd.
- Study start
- 15 Nov 2026 (estimated)
- Primary completion
- 30 Apr 2028 (estimated)
- Study completion
- 31 Jul 2028 (estimated)
- First posted
- 3 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine if Feru-guard, a dietary supplement, can decrease general oxidation and inflammation in people who are ages 65-89 years old. Also to determine if Feru-guard is safe in older people when given for 3 months.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Randomized, Double-Blind, Placebo-Controlled Study
| Arm | Type | Receives |
|---|---|---|
| Feru-guard | Experimental | Dietary Supplement: Feru-guardFeru-guard capsules |
| Placebo Group | Placebo comparator | Other: PlaceboPlacebo capsules that are matched in size, and color |
Who may qualify
- Ages
- 65 to 89 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (4 listed)
- 65 to 89 years old
- Not demented or mild cognitive impairment, defined as Clinical Dementia Rating (CDR) =0 and MMSE >24.
- Informant has direct contact with participant at least 2 days per week to verify functional status, CDR, and accompany participant to in-clinic screening visit
- Sufficient English language skills to complete all testing.
Key exclusion criteria (17 listed)
- Any dementing illness (AD, vascular dementia, normal pressure hydrocephalus, or Parkinson's disease); dementia defined by CDR ≥ 0.50, MMSE < 25
- AD medication (e.g. acetylcholinesterase inhibitors, NMDA receptor agonist, disease-modifying monoclonal antibody immunotherapy (e.g. lecanemab))
- Significant disease of the CNS such as brain tumor, seizure disorder, subdural hematoma, cranial arteritis
- Alcohol or substance abuse according to DSM-IV criteria within the last 2 years
- Major depression, schizophrenia, or other major psychiatric disorder defined by DSM-IV criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Feru-guardFerulic acid and Angelica dietary supplement in capsules | Dietary supplement | Feru-guard |
| PlaceboPlacebo capsules | Other | Placebo Group |
Primary outcome
Anti-oxidant Measure
Time frame: 12 Weeks
general oxidative stress marker malondialdehyde (MDA),
general oxidative stress marker malondialdehyde (MDA),
Time frame: 12 weeks
Anti-inflammatory measure
Time frame: 12 weeks
an inflammatory marker tumor necrosis factor alpha (TNF-alpha).
1 secondary outcome
Adverse Events
Time frame: 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Healthy Elder People
Active, not recruiting
CYCLE-AD (CYcling to Cease or Limit the Effects of Alzheimer's Disease)
High Intensity Exercise, Normal Cognition
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Feru-guard in people with Healthy Elder People, run by Oregon Health and Science University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lynne Shinto, ND, MPH ((503) 494-5035, shintol@ohsu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anti-oxidant Measure (time frame: 12 Weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.